AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Roivant Sciences Ltd (NASDAQ:ROIV)
11.435 USD
-0.005 0.044%Sponsored Reports
Loading...
| Previous Close (in USD) | 11.44 |
|---|---|
| Change | -0.005 0.044% |
| 52 W H/L (in USD) | 13.240/8.245 |
| EBITDA (in USD) | -1025.346M |
| PE Ratio | 2.08 |
| Volume | 2800297 |
| Diluted Eps TTM | 5.20 |
| Total Assets (in USD) | 2389.604M |
|---|---|
| Total Liabilities (in USD) | 782.017M |
| Revenue TTM (in USD) | 123.241M |
| Cash (in USD) | 1676.813M |
| Market Cap (in USD) | 8,727.312 M |
| Revenue Per Share TTM | 0.160 |
| Gross Profit TTM (in USD) | -477.063M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Roivant Sciences Ltd
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
Employees: 904
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Vivek Ramaswamy | Founder & Chairman | 1985 |
| 2. | Mr. Matthew Gline | CEO & Director | 1984 |
| 3. | Dr. Eric Venker M.D., Pharm.D. | Pres & COO | 1987 |
| 4. | Dr. Mayukh Sukhatme M.D. | Pres & Chief Investment Officer | 1976 |
| 5. | Mr. Richard Pulik | Chief Financial Officer | 1979 |
| 6. | Ms. Rakhi Kumar | Chief Accounting Officer | 1980 |
| 7. | Dr. Huafeng Xu Ph.D. | Chief Technology Officer | NA |
| 8. | Mr. Josh Chen | Gen. Counsel | NA |
| 9. | Ms. Kelly Graff | Head of People | NA |
| 10. | Ms. Marianne L. Romeo | Head of Global Transactions & Risk Management | 1968 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.365 0.493% | 73.84 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-1.320 1.776% | 73 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-9.585 2.138% | 451.26 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-3.910 0.761% | 521.05 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-03-2023 | 31-03-2022 | 31-03-2021 | 31-03-2020 | 31-03-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -1224.834M | -923.747M | -898.547M | - | - |
| Minority Interest | -106.433M | -78.854M | 264.217M | 76.533M | 220.346M |
| Net Income | -1230.024M | -924.116M | -900.233M | - | - |
| Selling General Administrative | 600.506M | 775.033M | 259.878M | - | - |
| Gross Profit | 48.152M | 46.32M | 21.738M | - | - |
| Reconciled Depreciation | 18.857M | - | - | - | - |
| Ebit | -1077.569M | -1211.748M | -1070.898M | -532.425M | -748.49M |
| Ebitda | -1107.578M | -1499.83M | -510.503M | - | - |
| Depreciation And Amortization | -30.009M | -288.082M | 560.395M | - | - |
| Operating Income | -1077.569M | -1211.748M | -1070.898M | - | - |
| Other Operating Expenses | 1138.849M | 1267.034M | 498.561M | - | - |
| Interest Expense | 27.968M | 7.041M | 2.809M | 0M | 0M |
| Tax Provision | 5.19M | 0.369M | 1.686M | - | - |
| Interest Income | 32.184M | 0.369M | 1.418M | - | - |
| Net Interest Income | 4.216M | -6.672M | -1.391M | - | - |
| Income Tax Expense | 5.19M | 0.369M | 1.686M | 7.124M | 2.624M |
| Total Revenue | 61.28M | 55.286M | 23.795M | - | - |
| Total Operating Expenses | 1125.721M | 1258.068M | 496.504M | - | - |
| Cost Of Revenue | 13.128M | 8.966M | 2.057M | - | - |
| Total Other Income Expense Net | -147.265M | 288.001M | 172.351M | - | - |
| Net Income From Continuing Ops | -1230.024M | -924.116M | -900.233M | - | - |
| Net Income Applicable To Common Shares | -1009.03M | -845.262M | -809.234M | 1122.732M | -1041.969M |
Balance Sheet
(Currency in USD)| Breakdown | 31-03-2023 | 31-03-2022 | 31-03-2021 | 31-03-2020 | 31-03-2019 |
|---|---|---|---|---|---|
| Total Assets | 2389.604M | 2585.129M | 2589.692M | - | - |
| Intangible Assets | 144.881M | - | - | - | - |
| Other Current Assets | 121.774M | 82.22M | 54.25M | 4.415M | 308.735M |
| Total Liab | 782.017M | 546.186M | 527.687M | - | - |
| Total Stockholder Equity | 1607.587M | 2038.943M | 1797.788M | - | - |
| Other Current Liab | 15.076M | 128.239M | 180.18M | 5.352M | 97.825M |
| Common Stock | - | - | - | - | - |
| Capital Stock | 0M | 0M | 0M | - | - |
| Retained Earnings | -3772.754M | -2763.724M | -1918.462M | -1109.228M | -2309.737M |
| Good Will | - | - | - | - | - |
| Other Assets | 49.482M | 25.823M | 36.128M | 90.429M | 22.723M |
| Cash | 1676.813M | 2060.4M | 2055.044M | - | - |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 272.448M | 184.367M | 218.961M | 92.118M | 211.268M |
| Current Deferred Revenue | 167.129M | 10.147M | 5.918M | - | - |
| Net Debt | -1195.409M | -1776.509M | -1810.067M | - | - |
| Short Term Debt | 52.413M | 11.398M | 12.313M | - | - |
| Short Long Term Debt | 40.72M | - | - | - | - |
| Short Long Term Debt Total | 481.404M | 283.891M | 244.977M | - | - |
| Other Stockholder Equity | 5382.958M | 4803.613M | 3714.805M | -2.349M | 2.518M |
| Property Plant Equipment | 39.086M | 25.905M | 77.028M | 73.932M | 11.111M |
| Total Current Assets | 1798.587M | 2146.523M | 2186.995M | 2219.245M | 1185.476M |
| Long Term Investments | 304.317M | 325.834M | 289.541M | - | - |
| Short Term Investments | 15.302M | 13.634M | - | - | - |
| Net Receivables | 32.735M | 6.732M | - | 15.279M | 10.97M |
| Long Term Debt | 375.515M | 210.025M | 170.28M | - | - |
| Inventory | 2.761M | - | - | - | - |
| Accounts Payable | 37.83M | 34.583M | 20.55M | 10.306M | 6.233M |
| Accumulated Other Comprehensive Income | -2.617M | -0.946M | 1.445M | - | - |
| Non Currrent Assets Other | 49.482M | 25.823M | 36.128M | - | - |
| Non Current Assets Total | 591.017M | 438.606M | 402.697M | - | - |
| Capital Lease Obligations | 65.169M | 73.866M | 74.697M | - | - |
| Long Term Debt Total | 375.515M | 210.025M | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-03-2023 | 31-03-2022 | 31-03-2021 | 31-03-2020 | 31-03-2019 |
|---|---|---|---|---|---|
| Investments | -44.269M | 320.17M | 320.17M | -51.936M | -43.613M |
| Total Cashflows From Investing Activities | -44.269M | 303.295M | -31.702M | 1694.79M | -57.608M |
| Total Cash From Financing Activities | 499.462M | 306.792M | 456.264M | 214.081M | 766.29M |
| Net Income | -1115.463M | -924.116M | -900.233M | 1200.509M | -1041.969M |
| Change In Cash | -381.919M | -67.642M | -127.576M | 1150.121M | -314.82M |
| Begin Period Cash Flow | 2074.034M | 2141.676M | 2269.252M | - | - |
| End Period Cash Flow | 1692.115M | 2074.034M | 2141.676M | 2269.252M | - |
| Total Cash From Operating Activities | -843.393M | -677.729M | -552.138M | -758.75M | -1023.502M |
| Depreciation | 18.857M | 5.932M | 5.932M | 5.932M | - |
| Other Cashflows From Investing Activities | -31.579M | 0.561M | -25.896M | -25.896M | -25.896M |
| Dividends Paid | 162.713M | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | 0.316M | - | - | - | - |
| Other Cashflows From Financing Activities | 312.295M | 328.382M | 0.508M | 153.184M | 400.553M |
| Capital Expenditures | 12.69M | 17.436M | 5.806M | 4.916M | 11.396M |
| Change In Working Capital | 6.345M | 15.719M | 71.938M | - | - |
| Other Non Cash Items | 33.446M | -334.288M | 191.199M | - | - |
| Free Cash Flow | -856.083M | -695.165M | -557.944M | - | - |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Morgan Stanley Insight A | 1 year ago | 2048037 |
| 2. | Morgan Stanley Insight | 1 year ago | 2048037 |
| 3. | Fidelity Extended Market Index | 1 year ago | 1948268 |
| 4. | State St S&P Midcap® Indx SL Cl II | 1 year ago | 1620400 |
| 5. | Fidelity Growth Compy Commingled Pl O | 1 year ago | 14474222 |
| 6. | Fidelity Growth Company Fund | 1 year ago | 10865857 |
| 7. | iShares Core S&P Mid-Cap ETF | 1 year ago | 10477936 |
| 8. | SPDR® S&P Biotech ETF | 1 year ago | 6666669 |
| 9. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 5023637 |
| 10. | Fidelity Select Biotechnology | 1 year ago | 3856619 |
| 11. | Morgan Stanley Growth SMA | 1 year ago | 3789733 |
| 12. | Morgan Stanley Inst Growth I | 1 year ago | 3789733 |
| 13. | Morgan Stanley Growth | 1 year ago | 3789733 |
| 14. | iShares Biotechnology ETF | 1 year ago | 3570108 |
| 15. | Fidelity Growth Company K6 | 1 year ago | 3528158 |
| 16. | SPDR® S&P MIDCAP 400 ETF Trust | 1 year ago | 2749055 |
| 17. | Fidelity Series Growth Company | 1 year ago | 2731200 |
| 18. | First Trust Health Care AlphaDEX® ETF | 1 year ago | 2593998 |
| 19. | MS INVF US Growth I | 1 year ago | 2567379 |
| 20. | State St Russell Sm/Mid Cp® Indx NL Cl C | 1 year ago | 2231600 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Qvt Financial LP | 1 year ago | 112541536 |
| 2. | SB INVESTMENT ADVISERS (UK) LTD | 1 year ago | 73031667 |
| 3. | Viking Global Investors LP | 1 year ago | 69368961 |
| 4. | FMR Inc | 1 year ago | 36976248 |
| 5. | Morgan Stanley - Brokerage Accounts | 1 year ago | 21927044 |
| 6. | BlackRock Inc | 1 year ago | 20805601 |
| 7. | Rubric Capital Management LP | 1 year ago | 19000000 |
| 8. | State Street Corporation | 1 year ago | 13727418 |
| 9. | Wellington Management Company LLP | 1 year ago | 13640416 |
| 10. | Patient Square Capital | 1 year ago | 12639920 |
| 11. | Two Seas Capital LP | 1 year ago | 8508223 |
| 12. | Baker Bros Advisors LP | 1 year ago | 7593024 |
| 13. | Farallon Capital Management, L.L.C. | 1 year ago | 7336000 |
| 14. | Vanguard Group Inc | 1 year ago | 7075651 |
| 15. | Woodline Partners LP | 1 year ago | 6151767 |
| 16. | Geode Capital Management, LLC | 1 year ago | 5524576 |
| 17. | Adage Capital Partners Gp LLC | 1 year ago | 5275000 |
| 18. | Anchorage Advisors, LLC | 1 year ago | 4832642 |
| 19. | venBio Select Advisor LLC | 1 year ago | 4651162 |
| 20. | Octagon Capital Advisors LP | 1 year ago | 4367000 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...